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Abstract 
 
Reliability of kinetic parameters are crucial in understanding enzyme kinetics within 
cellular system. The present study suggests a few cautions that need introspection for 
estimation of parameters like MK , MaxV and IK using Lineweaver-Burk plots. The quality 
of 50IC  too needs a thorough reinvestigation because of its direct link with IK  and MK  
values. Inhibition kinetics under both steady-state and non-steady-state conditions are 
studied and errors in estimated parameters are compared against actual values to settle the 
question of their adequacy. 
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1. Introduction 
 
Since the publication of the seminal paper [1] of Michaelis and Menten (MM) on 
enzyme kinetics in 1913, molecular biology has evolved tremendously. Nevertheless, the 
importance of century-old MM kinetics has not faded away [2]. It is still used in several 
contexts. Inhibition kinetics of enzyme characterization in large biochemical network is 
one such area. Many drugs alter the activity of specific enzymes within our body. 
Therefore, enzyme inhibition studies are routinely conducted [3-4] to assess the presence 
and magnitude of drug-drug interaction. Estimating the inhibition constant ( IK ) is 
particularly important in this regard. It offers a critical information for a specific drug. 
Another popular alternative measure is 50IC , the anagonistic drug potency, telling us the 
concentration of a drug that must be present in the body to achieve a desired degree of 
enzyme inhibition.  
This article concentrates on competitive reversible inhibitors that interact with 
enzymes to alter either their substrate binding affinity, or catalytic activity, or both. 
Extracting values for MM parameters for a given enzyme so as to quantify the effect of 
inhibition is identified as a nonlinear optimization problem. Over the years, various 
methods [4-7] to determine the kinetic parameters like MK , MaxV  and IK  have been 
proposed in presence of inhibitors. The statistical limitation of such parametric 
estimations [8-11] is also known. Graphical estimates are, however, much more common. 
But, they do not provide any assessment of errors of calculated data. This include the 
most popular Lineweaver-Burk (LB) plot [2, 6], and even the advanced scheme of 
Eisenthan and Cornish-Bowden [5-7, 12-14]. This is where our article intends to strike a 
note. A further insight into the legitimacy of the quasi-steady state approximation 
(QSSA) [15-17] is checked in the context of errors in IK  estimation through LB plots. 
Indeed, we notice minimum error in estimated values under QSSA conditions only, and 
that too under specific circumstances, to be pointed out in due course. 
2. The scheme 
 
In competitive inhibition (CI), substrate and inhibitor that bind to free enzyme are 
mutually exclusive. CI acts only to increase the MM constant for the substrate. The 
scheme is popularly designated as 
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We employ the following dimensionless variables for study: 
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This scaling scheme has elsewhere [16] been found to be quite convenient, though other 
possibilities exist [12, 14]. The coupled kinetic equations that follow from the scheme 
then reduce to 
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The constants iK  (i = 1, . . , 4) are given by 
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In addition, we have three mass-conservation equations 
                                    0 0 0; ;α α γ ν ξ ξ ν β β γ δ= + + = + = + +                                    (7) 
The kinetic pathway is simulated numerically over time. Simulation does not presuppose 
QSSA for the catalytic path or rapid-equilibrium for the inhibitory route, as often 
assumed while elucidating competitive inhibition kinetics. Numerical simulation shows 
the temporal profile of the complex γ passing through a maximum, and the corresponding 
time is referred to as Cτ . This time Cτ  is a measure of the ’transient phase’. For 
convenience, the scaled concentrations at Cτ are designated by Cβ , Cγ  and Cξ .The 
appropriate Lineweaver-Burk equation [16] for the kinetics under such condition is 
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Equation (8), however, assumes only that 0d dγ τ =  at Cτ τ= . If we additionally impose 
the rapid equilibrium condition, i.e., 0d dν τ = , and also insist that 0Cξ ξ= , then (8) 
reduces to the well-accepted form 
                                     01 1 1M
C C I
K
K
ξ
γ β
⎛ ⎞= + +⎜ ⎟⎝ ⎠
                                                                  (9) 
Here,  MK  (in scaled form) in Equations. (8) and (9) is given by 2 1( 1)K K+ . For brevity, 
we mention here that, in our scaled formulation, rate of reaction is proportional to the 
complex concentration. Hence, our LB plot takes 1 Cγ  as the ordinate and shows the 
variation against 1 Cβ  [16]. 
Estimation of IK  is concluded from the equation 
                                                   01M
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K
K K
ξ⎛ ⎞′ = +⎜ ⎟⎝ ⎠                                                             (10) 
where MK  and MK ′ are MM constants in absence and presence of inhibitors, respectively. 
The potential enzyme inhibition of a drug is quantified [18-23] in terms of 50IC  value 
where reversible inhibition is a desired mode of action. Popular Cheng-Prusoff equation 
[19] is used for such estimation via the relation 
                                                    50 1I
M
SIC K
K
⎛ ⎞= +⎜ ⎟⎝ ⎠
                                                     (11) 
In equation (11), S denotes the particular substrate concentration at which 50IC  is 
calculated for an enzyme assay in a particular laboratory concentration. 
3. Results and discussion 
In our exploration, we choose two reported literature data of vital physiological 
relevance. System 1 [24] corresponds to an in-vitro kinetic inhibition study of 
acetylcholine esterase with galanthame as inhibitor, declared as a case of CI in 
Alzeheimer disease. Inhibitors of acetylcholine breakdown by acetylcholine esterase 
constitute the main therapeutic modality of Alzheimer’s disease. System 2 data [9] refer 
to an in vitro interaction study of coumarin and pilocarpine with cytochrome 
450P inhibitor. The interest here lies in analyzing metabolic reactions catalyzed by human 
liver microsomes. This is also a CI case. 
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Table 1 summarizes the findings of our study for two different sets of reported 
predictor variables classified as System 1 and System 2. All concentrations are expressed 
in Mμ unit. Our systems under study are characterized by the following values of kinetic 
parameters: 
System 1: ( MK  = 26.3, MaxV  = 65.0, IK  = 3.4) 
System 2: ( MK  = 10.0, MaxV  = 0.1, IK  = 5.0) 
We further distinguish the systems as follows: 
System 1A: k1 = 5.0E(+02), k2 = 11.80E(+03), k3 = 1.30E(+03), e0 = 5.0E(-02) 
System 1B: k1 = 5.0E(-01), k2 = 6.65E(+0), k3 = 6.5E(+0), e0 = 1.0E(+01) 
System 2A: k1 = 1.5E(+02), k2 = 1.49E(+02), k3 = 1.0E(+01), e0 = 1.0E(-02) 
System 2B: k1 = 5.0E(-02), k2 = 4.0E(-01), k3 = 1.0E(-01), e0 = 1.0E(+0) 
 
Table 1: Literature values ( ,I LitK ) and calculated estimates ( ,I CalK ) of IK  for chosen rate constants 
at QSSA (1A, 2A) and non-QSSA (1B, 2B) conditions are shown, along with errors incurred. 
 
Systems 
 
E0 Run K4 K5 KI, Lit KI, Cal Error%
1A 0.05 1 
2 
3 
10.0 
100.0 
1000.0 
34.0 
340.0 
3400.0 
 
3.4 
18.264 
3.997 
3.451 
437.17 
17.56 
1.2 
1B 10.0 1 
2 
3 
0.1 
1.0 
10.0 
0.34 
3.4 
34.0 
 
3.4 
 
67.958 
10.043 
5.645 
1898.76 
95.38 
66.03 
2A 0.01 1 
2 
3 
1.0 
10.0 
100.0 
5.0 
50.0 
500.0 
 
5.0 
12.567 
6.97 
5.027 
151.34 
39.4 
0.54 
2B 1.0 1 
2 
3 
0.1 
1.0 
10.0 
0.5 
5.0 
50.0 
 
5.0 
9.64 
7.69 
5.82 
92.8 
53.8 
16.4 
 
For a given set of reported MK , MaxV  and IK  , the rate constants for the catalytic route 
and inhibitory path are constructed such that the scheme can be followed both under 
QSSA and non-QSSA regime. In the present study, A refers to the cases that obey the 
QSSA, while B represents situations under non-QSSA category. 
With each of the above sets of parameters, simulation has been carried out with 
seven different scaled substrate concentrations (10-70) for a definite strength of inhibitor 
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(ξ0 = 0.5) and one control (i.e., no inhibitor). The specific rate constants ( 4 5,k k ) for the 
binding and dissociation of the inhibitor-enzyme complex are altered keeping the 
equilibrium ratio intact to ensure a gradual transition from slow to rapid equilibrium for 
the path. These correspond to different runs. 
Another point of interest lies in the estimation of 50IC . Both 50IC  and IK  are 
measures of an inhibitor’s ability to block enzyme action. But, they are not equivalent. 
IK  values are the intrinsic properties of particular enzyme-inhibitor pairs and provide 
more reliable estimates of inhibitor potency, in contrast to 50IC  data that vary with 
substrate concentration and laboratory enzyme assay conditions. However, in view of 
equation (11), errors in 50IC  would be similar to those in IK . 
Important observations from the above study are now listed below: 
(i) Estimated IK  is in good agreement with literature data for cases assessed under QSSA 
condition for the catalytic route and rapid equilibrium for the inhibitory path. System 1A 
(3) and 2A (3) reveal this feature transparently. 
(ii) An appreciable rate of the inhibitory path is sufficient for a smaller error quote for 
QSSA, whereas, even rapid equilibrium is inadequate for error drop in the non-QSSA 
regime. A comparison between systems 1A (3) and 1B (3) or systems 2A (3) and 2B (3) 
would make it clear. 
(iii) For non-QSSA cases, e.g., systems 1B and 2B (see Table 1), an initial reduction in 
error quote finally saturates to a value even if the order of rate constants for the inhibitory 
path are higher than the catalytic path. This implies, rapid equilibrium cannot ensure a 
worthy estimate of IK  via linear regression. 
(iv) LB plots for the test cases, are, however, all linear without raising any doubt on the 
erroneous predictions of data. For example, both the Figure 1 and Figure 2 show that the 
LB plot is linear irrespective of whether QSSA is valid or not, or error estimates in IK  is 
large or small. 
(v) QSSA and rapid equilibrium provide a conducive environment for precise data 
estimation, whereas non-QSSA, even with a rapid equilibrium condition, might not be a 
suitable criterion for accurate prediction of IK . Another complimentary observation is the  
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Figure 1: Linear LB plot for System 1A (a) worst IK  for 1A (1) (b) best IK  for 1A (3). 
 
Figure 2: Linear LB plot for System 1B (i) worst IK  for 1B (1) (ii) best IK  for 1B (3). 
 
Figure 3: Plot of Cτ  vs substrate concentration ( 0β ) System 1A and 1B. 
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low variation in Cτ values for cases satisfying QSSA compared to those in the non-QSSA 
regime, as evident from Figure 3 and Figure 4. Approximate constancy in Cτ  may be an 
indication of QSSA. 
 
Figure 4: Plot of Cτ  vs substrate concentration ( 0β ) for System 2A and 2B. 
 
 
Figure 5: Plot of IK  vs 0I  for System 1A. 
 
(vi) The question of ensuring a rapid equilibrium between enzyme and inhibitor may be 
settled by varying the inhibitor concentration. Figure 5 sums up our observation for 
system 1A. The estimated IK passes through a minimum for a definite 0I value, and also 
for a definite set of binding and dissociation constants, for the chosen inhibition path. 
Steep rise in the IK  value with changing inhibitor concentration is an indication that one 
is on a wrong direction in data estimation. When the rate constants are altered, the 
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minima in IK  gradually saturate to the actual value, as shown in Figure 5. For any 
specific physiological process, however, the constraint lies in altering the biological rate 
constants. A bypass is to follow the variation with 0I and report data at the minimum 
point. 
4. Conclusion 
The purpose of this study has been to put a caution on the rampant use of LB plot 
[2, 25-28] in analyzing in vitro enzyme inhibition data, subsequently obtaining IK . The 
primary questions posed are (a) whether linearity of LB plot is enough to rely on 
estimated IK  [29-30] without scrutinizing QSSA and non-QSSA regime, (b) whether 
reliability of such estimates depends on the adequacy of the QSSA, (c) whether an 
inhibitor ensuring rapid equilibrium condition provides better estimates of IK  and (d) 
how to improve the error estimates and implement the method routinely for a robust 
estimate of IK  minimizing the uncertainties involved therein. 
Going through our analysis and computations for reversible CI, the following conclusions 
can be drawn: 
(i) Situations where QSSA hold, and where inhibitors ensure rapid equilibrium condition, 
IK  estimates are almost error free (see Table 1).  
(ii) An observed linearity in LB plot may be quite misleading (see, e.g., Figures 1 and 2) 
in respect of the validity of QSSA, and hence the sanctity of IK  values observed 
subsequently. 
(iii) A virtual consistency of Cτ  over large region of starting substrate concentration (see, 
e.g., Figures 3 and 4) is suggestive of whether QSSA holds for a particular case of 
enzyme-substrate-inhibitor combination under investigation. 
(iv) The establishment of rapid equilibrium in the QSSA regime can be ensured by 
altering the inhibitor concentration to encounter a minimum in IK . Lack of such a 
minimum (cf. Figure 5) will definitely warrant an attention for a new choice of enzyme-
inhibitor pair. 
In fine, we have illustrated a potential pitfall and remedial strategies for 
competitive inhibitors. The case of CI has been specifically chosen because it provides 
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the most common pathway for drug-drug interactions. However, the same route can be 
routinely adopted for other inhibitor types as well. We hope, our effort will increase the 
awareness about errors incurred in IK  (or 50IC ) calculations, limiting their input in drug-
dosage and drug-drug interactions in pharmaceutical industry. Some of our more 
interesting theoretical observations, displayed in Figures 3-5, may turn out to be useful 
guides to experimenters. 
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